Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

Spexin harmone may play role in weight gain among teenagers

Spexin harmone may play role in weight gain among teenagers

A Mayo Clinic-led study found that obese teenagers have lower levels of a hormone potentially tied to weight management than teens of normal weights. The study is published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Obese teenagers may have lower levels of spexin harmone

Obese teenagers may have lower levels of spexin harmone

Obese teenagers already show signs of hormonal differences from normal-weight peers that may make them prone to weight gain, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Majority of patients who misuse drugs and alcohol have chronic pain

Majority of patients who misuse drugs and alcohol have chronic pain

With opioid addiction and prescription drug abuse considered one of the biggest public health threats of our time in the U.S., many are asking why so many Americans are struggling with addiction to illegal drugs and prescription medications. New research suggests that chronic pain may be part of the answer. [More]
Scientists unveil reasons why NSAIDs, pain killers may increase heart disease risk

Scientists unveil reasons why NSAIDs, pain killers may increase heart disease risk

Researchers have known for more than a decade that the risk of heart disease and stroke increases when people take pain relievers like ibuprofen and other non-steroidal anti-inflammatory drugs, or NSAIDs. Now, scientists from the University of California, Davis, have uncovered some of the reasons why these drugs can harm heart tissue. [More]
Study shows overall drop in ER visits among patients served by prescription assistance program

Study shows overall drop in ER visits among patients served by prescription assistance program

A graduate student at Washington State University Spokane is the lead author on a research paper that shows an overall drop in emergency room visits and hospitalizations by patients who are served by the Spokane Prescription Assistance Network, which helps low income people get free and reduced-price medications. [More]
Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston. [More]
Opioids could be dangerous, deadly at high doses

Opioids could be dangerous, deadly at high doses

Most people know that heroin is a dangerous drug, but its cousins, the legal, pharmaceutical opioids, such as codeine or hydrocodone, must be safe, right?Not so fast.Opioids—which include the illegal drug heroin as well as prescription medications, including hydrocodone (such as Vicodin), oxycodone (such as OxyContin and Percocet), morphine and codeine—can be dangerous, even deadly, at high doses. [More]
New report offers startling statistics about chronic kidney disease in the U.S.

New report offers startling statistics about chronic kidney disease in the U.S.

A sweeping new report assessing chronic kidney disease in the United States offers startling statistics about a condition that affects almost 14 percent of the U.S. population and costs billions in Medicare spending each year. [More]
High out-of-pocket costs linked to lower use of specialty drugs

High out-of-pocket costs linked to lower use of specialty drugs

"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. [More]
Incretin-based drugs do not increase risk of heart failure

Incretin-based drugs do not increase risk of heart failure

Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study published in the New England Journal of Medicine. [More]
Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Among older adults with diabetes, certain subgroups--including white patients and those with lower incomes--were slower to discontinue the diabetes drug rosiglitazone after a US Food and Drug Administration safety alert, reports a study in the April issue of Medical Care. [More]
Aralez resubmits NDA package for YOSPRALA to FDA

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. [More]
Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc. [More]
Astellas, Medivation announce acceptance of XTANDI sNDA for review by FDA

Astellas, Medivation announce acceptance of XTANDI sNDA for review by FDA

Astellas Pharma Inc. and Medivation, Inc. today announced that the U.S. Food and Drug Administration has accepted for review a supplemental New Drug Application (sNDA) that they have submitted for XTANDI (enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. [More]
Research: Adenosine deaminase may help activate immune system against HIV

Research: Adenosine deaminase may help activate immune system against HIV

New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug. [More]
Temple University Hospital makes strides in confronting prescription drug abuse

Temple University Hospital makes strides in confronting prescription drug abuse

Prescription drug abuse has become a public health crisis in the U.S., and Temple University Hospital has made strides in confronting this critical situation. [More]
Meridian Health Plan named one of 'Best and Brightest Companies to Work For'

Meridian Health Plan named one of 'Best and Brightest Companies to Work For'

Meridian Health Plan, for the second time, has been nationally named one of the "Best and Brightest Companies to Work For" by the National Association for Business Resources. Previously, the NABR had consistently named Meridian as one of "Metropolitan Detroit's 101 Best and Brightest Companies to Work For" 2012 through 2015. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Nearly 7 in 10 middle and high school students exposed to e-cigarette ads

Nearly 7 in 10 middle and high school students exposed to e-cigarette ads

About 7 in 10 middle and high school students – more than 18 million young people – see e-cigarette advertising in stores, online, in newspapers and magazines, or on television and in movies, according to a new CDC Vital Signs report. [More]
Most patients with chronic pain continue to receive prescription opioids after nonfatal overdose

Most patients with chronic pain continue to receive prescription opioids after nonfatal overdose

A study led by Boston Medical Center indicates that most patients with chronic pain who are hospitalized after a nonfatal opioid overdose continue to receive prescription opioids after the overdose and are at high risk for experiencing a repeated overdose. [More]
Advertisement